Deals, Partnering

BioInvent signs licensing agreement with Daiichi Sankyo for discovery and development of therapeutic antibodies

Posted on 13 November 2009

Tags: ,

Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

BioInvent will receive an upfront access fee and annual maintenance fees for its antibody library, and success-based milestone payments. In addition, Daiichi Sankyo will also fund all research work and BioInvent is entitled to royalties on any commercialised products, as well as benefiting from the opportunity for selective co-promotion.

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
e79banner300x150gif
e78banner300x150animgif